Astrana Health, Inc.
NASDAQ:ASTHMedical - Care Facilities
+$1.03 today
- Market cap
- $1.47B
- Beta
- 0.94
- P/E (TTM)
- 63.3
- EPS (TTM)
- $0.62
Volume 0.52M
Average 0.51M
ASTH Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Astrana Health, Inc.NASDAQ: ASTH
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $9.9M rose 26.7% year over year, ahead of the +11.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 13.1% from the prior quarter. Over 3 fiscal years it compounded at +33.8% a year.
Context
- Stock-based compensation amounted to 1.2% of revenue in FY2025, down 0.5 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +26.7% holds above the trailing-twelve-month pace of +11.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 38.6M USD
- Year-over-year change
- +11.8%
- 4-year CAGR
- +54.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.6M | +11.8% |
| FY2024 | 2024-12-31 | 34.54M | +56.7% |
| FY2023 | 2023-12-31 | 22.04M | +36.9% |
| FY2022 | 2022-12-31 | 16.1M | +138.7% |
| FY2021 | 2021-12-31 | 6.75M | — |
Stock-Based Compensation vs competitors
How ASTH compares with its peers on the latest reported figures
- ASTH's LTM Mar 2026 stock-based compensation of $40.69M is the 2nd largest of the 4 companies compared; the peer median is $38.65M.
- Its year-over-year change of +11.2% is the 2nd highest of 4, against a peer median of -23.4%.
- Stock-based compensation amounts to 1.2% of revenue for ASTH, versus a peer median of 0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $85.45M | +62.2% | +751.4% | 9.7% | |
| LTM Mar 2026 | $40.69M | +11.2% | +33.8% | 1.2% | |
| LTM Mar 2026 | $38.65M | -23.4% | +20.1% | 0.7% | |
| LTM Jun 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding ASTH) | $38.65M | -23.4% | +385.7% | 0.7% | |
Competitors are the stored peer set for ASTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 46.06M | 45.74M | 57.85M | 49.93M | 24.08M |
| Depreciation & Amortization | 17.52M | 17.54M | 17.75M | 27.93M | 45.75M |
| Deferred Income Tax | 7.67M | (14.28M) | (12.44M) | (4.25M) | (4.29M) |
| Stock-Based Compensation | 6.75M | 16.1M | 22.04M | 34.54M | 38.6M |
| Change in Working Capital | (33.64M) | (1.96M) | (23.39M) | (63.61M) | (3.1M) |
| Accounts Receivables | (21.63M) | (33.97M) | (20.57M) | (11.1M) | (7.16M) |
| Inventory | (2.11M) | 27.61M | 12.16M | 0 | 0 |
| Accounts Payables | 4.11M | (2.52M) | (498K) | (30.43M) | (11.69M) |
| Other Working Capital | (14.01M) | 6.92M | (14.48M) | (22.09M) | 15.76M |
| Other Non-Cash Items | 25.99M | 18.98M | 6.42M | 7.67M | 13.56M |
| Operating Cash Flow | 70.34M | 82.13M | 68.23M | 52.2M | 114.6M |
| Capital Expenditures | (19.22M) | (22.94M) | (28.53M) | (8.03M) | (10.11M) |
| Acquisitions (Net) | (3.91M) | (18.46M) | (7.54M) | (156.14M) | (548.6M) |
| Purchases of Investments | (28M) | (1.85M) | (6.15M) | (2.61M) | 0 |
| Sales of Investments | 67.61M | 31.67M | 491K | 124K | 15.1M |
| Other Investing Activities | 56K | 4.47M | (23.8M) | (25.74M) | 4.61M |
| Investing Cash Flow | 16.54M | (7.11M) | (65.52M) | (192.4M) | (539M) |
| Debt Repayment | (58.69M) | (828K) | 79.17M | 152.71M | 604.81M |
| Common Stock Issued | 40.13M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (5.74M) | (9.25M) | (10.19M) | (937K) | (15.43M) |
| Dividends Paid | (31.09M) | (14.03M) | (62.07M) | (4.04M) | (7.89M) |
| Other Financing Activities | (1.42M) | 4.02M | (5.01M) | (12.59M) | (12.15M) |
| Financing Cash Flow | (47.75M) | (20.09M) | 3.42M | 135.15M | 569.35M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 39.13M | 54.93M | 6.13M | (5.05M) | 144.94M |
| Free Cash Flow | 51.11M | 59.19M | 39.7M | 44.17M | 104.49M |
Astrana Health, Inc.
NASDAQ:ASTH
Intrinsic Alpha fair value
Locked
Current Price
$29.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.